Qualigen Therapeutics Statistics
Total Valuation
QLGN has a market cap or net worth of $2.87 million. The enterprise value is $3.92 million.
Important Dates
The last earnings date was Thursday, November 14, 2024, after market close.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
QLGN has 736,431 shares outstanding. The number of shares has increased by 98.44% in one year.
| Current Share Class | 736,431 |
| Shares Outstanding | 736,431 |
| Shares Change (YoY) | +98.44% |
| Shares Change (QoQ) | +155.07% |
| Owned by Insiders (%) | 0.06% |
| Owned by Institutions (%) | 1.71% |
| Float | 735,986 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.52
| Current Ratio | 0.52 |
| Quick Ratio | 0.38 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.42 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -126.39% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.99M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -3,993 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -86.55% in the last 52 weeks. The beta is 0.15, so QLGN's price volatility has been lower than the market average.
| Beta (5Y) | 0.15 |
| 52-Week Price Change | -86.55% |
| 50-Day Moving Average | 5.21 |
| 200-Day Moving Average | 10.89 |
| Relative Strength Index (RSI) | 40.10 |
| Average Volume (20 Days) | 48,129 |
Short Selling Information
The latest short interest is 100,237, so 13.61% of the outstanding shares have been sold short.
| Short Interest | 100,237 |
| Short Previous Month | 94,369 |
| Short % of Shares Out | 13.61% |
| Short % of Float | 13.62% |
| Short Ratio (days to cover) | 0.11 |
Income Statement
| Revenue | n/a |
| Gross Profit | -2.55M |
| Operating Income | -6.70M |
| Pretax Income | -11.64M |
| Net Income | -7.94M |
| EBITDA | -6.89M |
| EBIT | -6.70M |
| Earnings Per Share (EPS) | -$41.53 |
Full Income StatementBalance Sheet
The company has $388,152 in cash and $1.43 million in debt, giving a net cash position of -$1.05 million or -$1.42 per share.
| Cash & Cash Equivalents | 388,152 |
| Total Debt | 1.43M |
| Net Cash | -1.05M |
| Net Cash Per Share | -$1.42 |
| Equity (Book Value) | -2.14M |
| Book Value Per Share | -3.90 |
| Working Capital | -2.14M |
Full Balance SheetCash Flow
| Operating Cash Flow | -9.73M |
| Capital Expenditures | n/a |
| Free Cash Flow | -9.73M |
| FCF Per Share | -$13.21 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |